Cisplatin biochemical mechanism of action: from cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways
Abstract
Although cisplatin, cis-diamminedichloroplatinum(II), has been successfully used in the chemotherapy of cancer for more than 25 years, its biochemical mechanism of action is still unclear. The current accepted paradigm about cisplatin mechanism of action is that the drug induces its cytotoxic properties through binding to nuclear DNA and subsequent interference with normal transcription, and/or DNA replication mechanisms. If cisplatin-DNA adducts are not efficiently processed by cell machinery, cytotoxic processes eventually end up in cell death. However, before cisplatin enters the cell it may bind to phospholipids and phosphatidylserine in the cell membrane. In addition, in the cytoplasm many potential platinum-binding sites are also available, including RNA and sulfur-containing biomolecules. Moreover, there is much evidence suggesting that the cytotoxic effects induced by binding of cisplatin to non-DNA targets (especially proteins) may contribute to its biochemical mechanism of action. On the other hand, it has been found that several factors such as the dose of drug as well as the metabolic condition of the cell subjected to cisplatin aggression, may determine that cancer cells die through apoptosis or necrosis. In fact, it has recently been reported that both mechanisms of cell demise work in concert so that within a population of tumour cells there is a continuum of possible modes of cell death.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Platinum agents such as cisplatin and carboplatin form DNA-platinum adducts that create intra- and interstrand crosslinks, leading to double-strand breaks and cell death.
“Platinum agents, such as cisplatin and carboplatin, form DNA-platinum adducts resulting in intra- and interstrand DNA crosslinks leading to increased double strand breaks and cell death (3).”
From Potentiation of carboplatin-mediated DNA damage by the Mdm2 modulator Nutlin-3a in a humanized orthotopic breast-to-lung metastatic model (2015) · cites this paper as [3]
Cites
Still being checked.
Cited by
Sorted by citations
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
Molina, J. R., Yang, P., Cassivi, S. D., Schild, S. E., & Adjei, A. A. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.5.584 · Cited by 3,927 · see citing works
Fuertes, M. A., Alonso‐Moreno, C., & Pérez, J. M. (2003) · Chemical Reviews · doi:10.1021/cr020010d · Cited by 896 · see citing works
Self-citationThe role of p53 in cancer drug resistance and targeted chemotherapy
Hientz, K., Mohr, A., Bhakta-Guha, D., & Efferth, T. (2016) · Oncotarget · doi:10.18632/oncotarget.13475 · Cited by 590 · see citing works
Approaching tumour therapy beyond platinum drugs
Bergamo, A., Gaiddon, C., Schellens, J. H. M., Beijnen, J. H., & Sava, G. (2011) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2011.09.030 · Cited by 515 · see citing works
Chiangjong, W., Chutipongtanate, S., & Hongeng, S. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.5099 · Cited by 391 · see citing works
Modifications of DNA by platinum complexes
Brabec, V., & Kašpárková, J. (2005) · Drug Resistance Updates · doi:10.1016/j.drup.2005.04.006 · Cited by 374 · see citing works
What do we know about the reduction of Pt(IV) pro-drugs?
Wexselblatt, E., & Gibson, D. (2012) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2012.06.013 · Cited by 372 · see citing works
Cisplatin and Aminoglycoside Antibiotics: Hearing Loss and Its Prevention
Schacht, J., Talaska, A. E., & Rybak, L. P. (2012) · The Anatomical Record · doi:10.1002/ar.22578 · Cited by 348 · see citing works
Platinum Anticancer Coordination Compounds: Study of DNA Binding Inspires New Drug Design
Reedijk, J. (2009) · European Journal of Inorganic Chemistry · doi:10.1002/ejic.200900054 · Cited by 343 · see citing works
Anticancer cyclometalated complexes of platinum group metals and gold
Cutillas, N., Yellol, G. S., Haro, C. D., Vicente, C., Rodrı́guez, V., & Ruiz, J. (2013) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2013.03.024 · Cited by 332 · see citing works
Chemotherapy Resistance in Advanced Ovarian Cancer Patients
Pokhriyal, R., Hariprasad, R., Kumar, L., & Hariprasad, G. (2019) · Biomarkers in Cancer · doi:10.1177/1179299x19860815 · Cited by 282 · see citing works
Shi, G., Monro, S. M. A., Hennigar, R. A., Colpitts, J., Fong, J., Kasimova, K., Yin, H., DeCoste, R. C., Spencer, C., Chamberlain, L., et al. (2014) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2014.04.012 · Cited by 280 · see citing works
Anti-inflammatory activity of nanocrystalline silver in a porcine contact dermatitis model
Nadworny, P. L., Wang, J., Tredget, E. E., & Burrell, R. E. (2008) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2008.04.006 · Cited by 272 · see citing works
Yang, Z., Schumaker, L. M., Egorin, M. J., Zuhowski, E. G., Guo, Z., & Cullen, K. J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1037 · Cited by 270 · see citing works
Pentamidine reverses the splicing defects associated with myotonic dystrophy
Warf, M. B., Nakamori, M., Matthys, C. M., Thornton, C. A., & Berglund, J. A. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903234106 · Cited by 265 · see citing works
Pyruvate dehydrogenase kinase as a novel therapeutic target in oncology
Sutendra, G., & Michelakis, E. D. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00038 · Cited by 263 · see citing works
Biophysics in cancer: The relevance of drug-membrane interaction studies
Alves, A. C., Ribeiro, D., Nunes, C., & Reis, S. (2016) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2016.06.025 · Cited by 245 · see citing works
Dickey, D. T., Wu, Y. J., Muldoon, L. L., & Neuwelt, E. A. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.087601 · Cited by 219 · see citing works
Ahmad, S. (2010) · Chemistry & Biodiversity · doi:10.1002/cbdv.200800340 · Cited by 215 · see citing works
Regulation of PUMA-α by p53 in cisplatin-induced renal cell apoptosis
Jiang, M., Wei, Q., Wang, J., Du, Q., Yu, J., Zhang, L., & Dong, Z. (2006) · Oncogene · doi:10.1038/sj.onc.1209440 · Cited by 211 · see citing works
Faubel, S. G., Ljubanović, D. G., Reznikov, L. L., Somerset, H., Dinarello, C. A., & Edelstein, C. L. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.66010.x · Cited by 196 · see citing works
Mitochondria as a critical target of the chemotheraputic agent cisplatin in head and neck cancer
Cullen, K. J., Yang, Z., Schumaker, L. M., & Guo, Z. (2007) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-006-9059-5 · Cited by 194 · see citing works
Doles, J., Oliver, T. G., Cameron, E. R., Hsu, G., Jacks, T., Walker, G. C., & Hemann, M. T. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1011409107 · Cited by 190 · see citing works
Raveendran, R., Braude, J. P., Wexselblatt, E., Novohradský, V., Stuchlíková, O., Brabec, V., Gandin, V., & Gibson, D. (2016) · Chemical Science · doi:10.1039/c5sc04205d · Cited by 183 · see citing works
The mechanism of action of platinum anticancer agents—what do we really know about it?
Gibson, D. (2009) · Dalton Transactions · doi:10.1039/b918871c · Cited by 181 · see citing works
Role of p53 in cisplatin-induced tubular cell apoptosis: dependence on p53 transcriptional activity
Jiang, M., Yi, X., Hsu, S., Wang, C., & Dong, Z. (2004) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00262.2004 · Cited by 175 · see citing works
Cisplatin for cancer therapy and overcoming chemoresistance
Ranasinghe, R., Mathai, M. L., & Zulli, A. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e10608 · Cited by 169 · see citing works
Docking Studies on DNA Intercalators
Gilad, Y., & Senderowitz, H. (2013) · Journal of Chemical Information and Modeling · doi:10.1021/ci400352t · Cited by 152 · see citing works
Role of the Glutathione Metabolic Pathway in Lung Cancer Treatment and Prognosis: A Review
Yang, P., Ebbert, J. O., Sun, Z., & Weinshilboum, R. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.7110 · Cited by 151 · see citing works
Jiang, M., Wei, Q., Pabla, N., Dong, G., Wang, C., Yang, T., Smith, S. B., & Dong, Z. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.01.010 · Cited by 148 · see citing works
Perspectives in bioinorganic chemistry of some metal based therapeutic agents
Ahmad, S., Isab, A. A., Ali, S., & Al‐Arfaj, A. R. (2005) · Polyhedron · doi:10.1016/j.poly.2005.11.004 · Cited by 147 · see citing works
Théon, A. P., Wilson, W. D., Magdesian, K. G., Pusterla, N., Snyder, J. R., & Galuppo, L. D. (2007) · Journal of the American Veterinary Medical Association · doi:10.2460/javma.230.10.1506 · Cited by 132 · see citing works
Protection against cisplatin-induced ototoxicity by N-acetylcysteine in a rat model
Dickey, D. T., Muldoon, L. L., Kraemer, D. F., & Neuwelt, E. A. (2004) · Hearing Research · doi:10.1016/j.heares.2004.02.007 · Cited by 130 · see citing works
Epidemiology of Lung Cancer Prognosis: Quantity and Quality of Life
Yang, P. (2009) · Methods in molecular biology · doi:10.1007/978-1-59745-416-2_24 · Cited by 122 · see citing works
Nguewa, P., Fuertes, M. A., Valladares, B., Alonso‐Moreno, C., & Pérez, J. M. (2004) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2004.01.001 · Cited by 119 · see citing works
Self-citationAnti-inflammatory activity of nanocrystalline silver-derived solutions in porcine contact dermatitis
Nadworny, P. L., Wang, J., Tredget, E. E., & Burrell, R. E. (2010) · Journal of Inflammation · doi:10.1186/1476-9255-7-13 · Cited by 120 · see citing works
Up-regulation of 14-3-3ζ in Lung Cancer and Its Implication as Prognostic and Therapeutic Target
Fan, T., Li, R., Todd, N. W., Qiu, Q., Fang, H.-B., Wang, H., Shen, J., Zhao, Y., Caraway, N. P., Katz, R. L., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0090 · Cited by 116 · see citing works
Bystander or No Bystander for Gene Directed Enzyme Prodrug Therapy
Dachs, G. U., Hunt, M. A., Syddall, S. P., Singleton, D. C., & Patterson, A. V. (2009) · Molecules · doi:10.3390/molecules14114517 · Cited by 110 · see citing works
Amifostine Protective Effect on Cisplatin‐Treated Rat Testis
Lirdi, L. C., Stumpp, T., Sasso‐Cerri, E., & Miraglia, S. M. (2008) · The Anatomical Record · doi:10.1002/ar.20693 · Cited by 113 · see citing works
Xiao, H., Noble, G. T., Stefanick, J. F., Qi, R., Kiziltepe, T., Jing, X., & Bilgiçer, B. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.10.020 · Cited by 104 · see citing works
MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer
Sun, N., Sun, X., Chen, B., Cheng, H., Feng, J., Cheng, L., & Lu, Z. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-1046-1 · Cited by 100 · see citing works
RB signaling prevents replication-dependent DNA double-strand breaks following genotoxic insult
Bosco, E. E. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkg919 · Cited by 97 · see citing works
Sava, G., Jaouen, G., Hillard, E. A., & Bergamo, A. (2012) · Dalton Transactions · doi:10.1039/c2dt30075c · Cited by 98 · see citing works
A dual-targeting, apoptosis-inducing organometallic half-sandwich iridium anticancer complex
Novohradský, V., Zerzánková, L., Štěpánková, J., Kisova, A., Kostrhunová, H., Liu, Z., Sadler, P. J., Kašpárková, J., & Brabec, V. (2014) · Metallomics · doi:10.1039/c4mt00112e · Cited by 97 · see citing works
Sala, E., Kataoka, M., Priest, A. N., Gill, A. B., McLean, M. A., Joubert, I., Graves, M. J., Crawford, R., Jimenez‐Liñan, M., Earl, H. M., et al. (2012) · Radiology · doi:10.1148/radiol.11110175 · Cited by 96 · see citing works
RNA-Pt Adducts Following Cisplatin Treatment ofSaccharomyces cerevisiae
Hostetter, A. A., Osborn, M. F., & DeRose, V. J. (2011) · ACS Chemical Biology · doi:10.1021/cb200279p · Cited by 95 · see citing works
Involvement of cytochrome P450 in cisplatin treatment: implications for toxicity
Quintanilha, J. C. F., de Sousa, V. M., Visacri, M. B., Amaral, L. S., Santos, R. M. M., Zambrano, T., Salazar, L. A., & Moriel, P. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3358-x · Cited by 95 · see citing works
Ramey, C. J., Howar, S. R., Adkins, M. W., Linger, J. G., Spicer, J., & Tyler, J. K. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.23.10313-10327.2004 · Cited by 95 · see citing works
Zhao, Y., Jing, Z., Li, Y., & Mao, W. (2016) · Oncology Reports · doi:10.3892/or.2016.4785 · Cited by 92 · see citing works
Novohradský, V., Zerzánková, L., Štěpánková, J., Vrána, O., Raveendran, R., Gibson, D., Kašpárková, J., & Brabec, V. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.04.003 · Cited by 91 · see citing works
Sohn, S.-J., Kim, S. Y., Kim, H. S., Chun, Y., Han, S. Y., Kim, S. H., & Moon, A. (2012) · Toxicology Letters · doi:10.1016/j.toxlet.2012.12.015 · Cited by 89 · see citing works
Fang, C. (2010) · International Journal of Oncology · doi:10.3892/ijo.2010.851 · Cited by 88 · see citing works
Molecular and Cellular Mechanisms of Cytotoxic Activity of Vanadium Compounds against Cancer Cells
Kowalski, S., Wyrzykowski, D., & Inkielewicz‐Stępniak, I. (2020) · Molecules · doi:10.3390/molecules25071757 · Cited by 88 · see citing works
Cisplatin Resistance: Genetic and Epigenetic Factors Involved
Lugones, Y., Loren, P., & Salazar, L. A. (2022) · Biomolecules · doi:10.3390/biom12101365 · Cited by 90 · see citing works
Cisplatin: an old drug with a newfound efficacy – from mechanisms of action to cytotoxicity
Macciò, A., & Madeddu, C. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.813934 · Cited by 86 · see citing works
Cisplatin electrochemical biosensor
Petrlová, J., Potěšil, D., Zehnálek, J., Sures, B., Adam, V., Trnková, L., & Kizek, R. (2006) · Electrochimica Acta · doi:10.1016/j.electacta.2006.03.077 · Cited by 86 · see citing works
Anti-tumor Efficiency of Lipid-coated Cisplatin Nanoparticles Co-loaded with MicroRNA-375
Tan, Y., Zhao, P., Rong, Z., Li, B., Xue, H., You, J., He, C., Li, W., He, X., Lee, R. J., et al. (2015) · Theranostics · doi:10.7150/thno.13130 · Cited by 81 · see citing works
Doucette, K. K., Hassell, K. N., & Crans, D. C. (2016) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2016.09.013 · Cited by 80 · see citing works
Anti-cancer drugs interfere with intracellular calcium signaling
Florea, A.-M., & Büsselberg, D. (2009) · NeuroToxicology · doi:10.1016/j.neuro.2009.04.014 · Cited by 79 · see citing works
Cellular interactions of platinum drugs
Wexselblatt, E., Yavin, E., & Gibson, D. (2012) · Inorganica Chimica Acta · doi:10.1016/j.ica.2012.07.013 · Cited by 77 · see citing works
Cytoplasmic initiation of cisplatin cytotoxicity
Yu, F., Megyesi, J. K., & Price, P. M. (2008) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00593.2007 · Cited by 77 · see citing works
Ma, Z., Li, Y., Li, W., Yan, X., Yang, G., Zhang, J., Zhao, L., & Yang, L. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071407 · Cited by 74 · see citing works
Prachařová, J., Zerzánková, L., Štěpánková, J., Nováková, O., Farrer, N. J., Sadler, P. J., Brabec, V., & Kašpárková, J. (2012) · Chemical Research in Toxicology · doi:10.1021/tx300057y · Cited by 74 · see citing works
Magnetic nanoparticle hyperthermia enhancement of cisplatin chemotherapy cancer treatment
Petryk, A. A., Giustini, A. J., Gottesman, R. E., Kaufman, P. A., & Hoopes, P. J. (2013) · International Journal of Hyperthermia · doi:10.3109/02656736.2013.825014 · Cited by 72 · see citing works
Programmed cell death in trypanosomatids: a way to maximize their biological fitness?
Nguewa, P., Fuertes, M. A., Valladares, B., Alonso‐Moreno, C., & Pérez, J. M. (2004) · Trends in Parasitology · doi:10.1016/j.pt.2004.05.006 · Cited by 72 · see citing works
Self-citationThe relationship between platinum drug resistance and epithelial–mesenchymal transition
Brozović, A. (2016) · Archives of Toxicology · doi:10.1007/s00204-016-1912-7 · Cited by 72 · see citing works
Conformation of DNA GG Intrastrand Cross-Link of Antitumor Oxaliplatin and Its Enantiomeric Analog
Malina, J., Nováková, O., Vojtı́šková, M., Natile, G., & Brabec, V. (2007) · Biophysical Journal · doi:10.1529/biophysj.107.116996 · Cited by 70 · see citing works
Shord, S. S., Thompson, D. M., Krempl, G. A., & Hanigan, M. H. (2006) · Anti-Cancer Drugs · doi:10.1097/00001813-200602000-00013 · Cited by 69 · see citing works
Kinetic aspects of platinum anticancer agents
Ahmad, S. (2017) · Polyhedron · doi:10.1016/j.poly.2017.09.016 · Cited by 68 · see citing works
The Current and Future Therapies for Human Osteosarcoma
Lamplot, J. D., Denduluri, S. K., Qin, J., Li, R., Liu, X., Zhang, H., Chen, X., Wang, N., Pratt, A., Shui, W., et al. (2013) · Current Cancer Therapy Reviews · doi:10.2174/1573394711309010006 · Cited by 67 · see citing works
A Suggestion of Electrochemical Biosensor for Study of Platinum(II)‐DNA Interactions
Křížková, S., Adam, V., Petrlová, J., Zítka, O., Stejskal, K., Zehnálek, J., Sures, B., Trnková, L., Beklová, M., & Kizek, R. (2007) · Electroanalysis · doi:10.1002/elan.200603737 · Cited by 65 · see citing works
Effects of oxaliplatin on mouse myenteric neurons and colonic motility
Wafai, L., Taher, M., Jovanovska, V., Bornstein, J. C., Dass, C. R., & Nurgali, K. (2013) · Frontiers in Neuroscience · doi:10.3389/fnins.2013.00030 · Cited by 65 · see citing works
Perez, J. M. T., Kèlland, L. R., Montero, E. I., Boxall, F. E., Fuertes, M. A., Alonso‐Moreno, C., & Navarro‐Ranninger, C. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.4.933 · Cited by 64 · see citing works
Self-citationAguirre, J. D., Lutterman, D. A., Angeles-Boza, A. M., Dunbar, K. R., & Turró, C. (2007) · Inorganic Chemistry · doi:10.1021/ic700708g · Cited by 64 · see citing works
Structural and mechanistic aspects of platinum anticancer agents
Ahmad, S., Isab, A. A., & Ali, S. (2006) · Transition Metal Chemistry · doi:10.1007/s11243-006-0100-7 · Cited by 61 · see citing works
MiR-218 regulates cisplatin chemosensitivity in breast cancer by targeting BRCA1
He, X., Xiao, X., Dong, L., Wan, N., Zhou, Z., Deng, H., & Zhang, X. (2014) · Tumor Biology · doi:10.1007/s13277-014-2814-z · Cited by 61 · see citing works
Is Autophagy Always a Barrier to Cisplatin Therapy?
Xu, J., & Gewirtz, D. A. (2022) · Biomolecules · doi:10.3390/biom12030463 · Cited by 60 · see citing works
Linear polyethyleneimine-based charge-reversal nanoparticles for nuclear-targeted drug delivery
Zhou, Z., Shen, Y., Tang, J., Jin, E., Ma, X., Sun, Q., Zhang, B., Kirk, E. A. V., & Murdoch, W. J. (2011) · Journal of Materials Chemistry · doi:10.1039/c1jm13576g · Cited by 59 · see citing works
PARP inhibition in platinum-based chemotherapy: Chemopotentiation and neuroprotection
McQuade, R. M., Stojanovska, V., Bornstein, J. C., & Nurgali, K. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.09.031 · Cited by 59 · see citing works
Immunohistochemical detection of platinated DNA in the cochlea of cisplatin-treated guinea pigs
van Ruijven, M. W. M., de Groot, J. C. M. J., Hendriksen, F. G. J., & Smoorenburg, G. F. (2005) · Hearing Research · doi:10.1016/j.heares.2004.12.007 · Cited by 58 · see citing works
Church, M. W., Blakley, B. W., Burgio, D. L., & Gupta, A. K. (2004) · Journal of the Association for Research in Otolaryngology · doi:10.1007/s10162-004-4011-z · Cited by 57 · see citing works
Mishra, A. K., Dormi, S. S., Turchi, A. M., Woods, D. S., & Turchi, J. J. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.10.013 · Cited by 57 · see citing works
Dai, C.-H., Chen, P., Li, J., Lan, T., Chen, Y., Qian, H., Chen, K., & Li, M. (2016) · Oncotarget · doi:10.18632/oncotarget.11214 · Cited by 57 · see citing works
Chifotides, H. T., Fu, P. K. ‐., Dunbar, K. R., & Turró, C. (2004) · Inorganic Chemistry · doi:10.1021/ic034438m · Cited by 57 · see citing works
Télétchéa, S., Komeda, S., Teuben, J., Elizondo-Riojas, M.-Á., Reedijk, J., & Kozelka, J. (2006) · Chemistry - A European Journal · doi:10.1002/chem.200500923 · Cited by 56 · see citing works
Youn, M., So, H., Cho, H.-J., Kim, H.-J., Kim, Y., Lee, J., Sohn, J. S., Kim, Y. K., Chung, S.-Y., & Park, R. (2008) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.31.789 · Cited by 55 · see citing works
Personalized Medicine for Targeted and Platinum-Based Chemotherapy of Lung and Bladder Cancer
Cimino, G. D., Pan, C.-X., & Henderson, P. T. (2013) · Bioanalysis · doi:10.4155/bio.12.325 · Cited by 55 · see citing works
Hypoxia-induced cisplatin resistance is reversible and growth rate independent in lung cancer cells
Wohlkoenig, C., Leithner, K., Deutsch, A. J. A., Hrzenjak, A., Olschewski, A., & Olschewski, H. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.03.014 · Cited by 55 · see citing works
Yu, K., Levine, D. A., Zhang, H., Chan, D. W., Zhang, Z., & Snyder, M. P. (2016) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5b01129 · Cited by 55 · see citing works
Kašpárková, J., Suchánková, T., Halámiková, A., Zerzánková, L., Vrána, O., Margiotta, N., Natile, G., & Brabec, V. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.09.019 · Cited by 54 · see citing works
Wang, S. J., & Bourguignon, L. (2006) · Archives of Otolaryngology - Head and Neck Surgery · doi:10.1001/archotol.132.1.19 · Cited by 54 · see citing works
Interleukin-6 modulates oxidative stress produced during the development of cisplatin nephrotoxicity
Mitazaki, S., Hashimoto, M., Matsuhashi, Y., Honma, S., Suto, M., Kato, N., Nakagawasai, O., Tan–No, K., Hiraiwa, K., Yoshida, M., et al. (2013) · Life Sciences · doi:10.1016/j.lfs.2013.01.026 · Cited by 53 · see citing works
Adenylate Kinase 3 Sensitizes Cells to Cigarette Smoke Condensate Vapor Induced Cisplatin Resistance
Chang, X., Ravi, R. K., Pham, V., Bedi, A., Chatterjee, A., & Sidransky, D. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020806 · Cited by 52 · see citing works
Mitochondrial/lysosomal toxic cross-talk plays a key role in cisplatin nephrotoxicity
Pourahmad, J., Hosseini, M., Eskandari, M. R., Shekarabi, S. M., & Daraei, B. (2010) · Xenobiotica · doi:10.3109/00498254.2010.512093 · Cited by 52 · see citing works
Pauzi, A. Z. M., Yeap, S. K., Abu, N., Lim, K. L., Omar, A. R., Aziz, S. A., Chow, A. L. T., Subramani, T., Tan, S. G., & Alitheen, N. B. (2016) · Chinese Medicine · doi:10.1186/s13020-016-0118-5 · Cited by 52 · see citing works
Li, Y., Ren, S., Yan, X., Li, H., Li, W., Zheng, B., Wang, Z., & Liu, Y. (2018) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2018.01.033 · Cited by 52 · see citing works
García-Friaza, G., Fernández‐Botello, A., Perez, J. M. T., Prieto, M. J., & Moreno, V. (2006) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2006.03.011 · Cited by 52 · see citing works
Cisplatin up‐regulates ICAM‐1 expression in endothelial cell via a NF‐κB dependent pathway
Yu, M., Han, J., Cui, P., Dai, M., Li, H., Zhang, J., & Xiu, R. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00696.x · Cited by 51 · see citing works
Marotta, C., Giorgi, E., Binacchi, F., Cirri, D., Gabbiani, C., & Pratesi, A. (2023) · Inorganica Chimica Acta · doi:10.1016/j.ica.2023.121388 · Cited by 50 · see citing works
Zhang, K., & Li, Y. (2015) · Pharmaceutical Biology · doi:10.3109/13880209.2015.1101142 · Cited by 49 · see citing works
- Authors
- Fuertes, M., Castilla, J., Alonso, C., & Pérez, J.
- Affiliations
- Universidad Autónoma de Madrid (ES)
- Corresponding author
- Castilla, J.
- Pérez, J.
- Venue
- Current Medicinal Chemistry
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2003-02-01
- Volume
- 10
- Issue
- 3
- Pages
- 257-266
- ISSN
- 0929-8673 (ISSN-L)
- OpenAlex
- W2146133266
- Cited by
- 432
- References
- 0
- Citations by year
- 2026: 3 · 2025: 14 · 2024: 31 · 2023: 38 · 2022: 21 · 2021: 14 · 2020: 17 · 2019: 13 · 2018: 15 · 2017: 21 · 2016: 22 · 2015: 15 · 2014: 30 · 2013: 28 · 2012: 27
- FWCI
- 5.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Fundación Ramón Areces
- Topics
- Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Keywords
- cisplatin, mechanism of action, DNA adducts, phospholipid binding, phosphatidylserine, RNA binding, cytotoxicity, apoptosis, necrosis, cell death pathways, platinum-based chemotherapy
- MeSH terms
- Animals, Antineoplastic Agents, Binding Sites, Cisplatin, DNA Damage, DNA Repair, Humans, Necrosis, Neoplasms, Cell Death, Apoptosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
